Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Obesity and type 2 diabetes].

M Rorive1, M R Letiexhe, A J Scheen

  • 1Université de Liège, Centre de l'Obésité, CHU Ourthe-Amblève, Esneux et Service de Diabétologie, Nutrition et Maladies métaboliques, CHU Sart Tilman, Liège.

Revue Medicale De Liege
|July 23, 2005
PubMed
Summary

Obesity is a major risk factor for cardiovascular diseases like diabetes and hypertension, often driven by insulin resistance. Effective management includes lifestyle changes, medications, and bariatric surgery for severe cases.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Sitagliptine (Januvia): incretin enhancer potentiating insulin secretion for the treatment of type 2 diabetes].

Revue medicale de Liege·2008
Same author

[Medication of the month. Rimonabant (Acomplia): first CB1 receptor antagonist of the endocannabinoid system].

Revue medicale de Liege·2008
Same author

[Isolated tricuspid valve endocarditis as a cause of fever of unknown origin].

Revue medicale de Liege·2008
Same author

[A first drug combination for the treatment of arterial hypertension with a calcium channel antagonist (amlodipine besylate) and an angiotensin receptor blocker (valsartan): Exforge].

Revue medicale de Liege·2008
Same author

[Therapy of type 2 diabetes: between insulin sensitizers and insulin secreting agents].

Revue medicale de Liege·2008
Same author

[Aspirin resistance in diabetic patients: laboratory entity or clinical reality?].

Revue medicale de Liege·2007

Area of Science:

  • Endocrinology and Metabolism
  • Cardiovascular Disease Research
  • Obesity Medicine

Context:

  • Obesity is a global epidemic linked to critical cardiovascular risk factors including diabetes mellitus, dyslipidemia, and hypertension.
  • Insulin resistance is a key mechanism promoting these metabolic abnormalities, with obesity, particularly abdominal adiposity, being a primary driver of type 2 diabetes.
  • Understanding these links is crucial for developing effective treatment strategies.

Purpose:

  • To outline the relationship between obesity, insulin resistance, and associated cardiovascular risk factors.
  • To review current and potential therapeutic approaches for managing obese individuals with type 2 diabetes.
  • To highlight the role of lifestyle modifications, pharmacotherapy, and bariatric surgery.

Summary:

Related Experiment Videos

  • Treatment for obese individuals with diabetes mellitus commences with lifestyle interventions such as diet, physical activity, and psychological support.
  • Pharmacological options include agents promoting weight loss (e.g., orlistat, sibutramine) and antihyperglycemic drugs that reduce insulin resistance (e.g., metformin, glitazones, acarbose).
  • For severe or morbid obesity with poorly controlled type 2 diabetes, bariatric surgery offers significant and sustained weight loss, improving metabolic control and prognosis.

Impact:

  • Provides a comprehensive overview of obesity's impact on cardiovascular health and type 2 diabetes.
  • Informs clinical decision-making regarding the stepwise management of obese diabetic patients.
  • Emphasizes the potential of bariatric surgery as a definitive treatment for severe, complex cases.